Abstract:We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR). Our previous study showed that the population of cell-surface expressed EGFRs in A431 cells, a human epidermoid carcinoma cell line, is composed of two subpopulations that differ by glycosylation at N(579) [Zhen et al. (2003) Biochemistry 42, 5478-5492]. To characterize the subpopulation of receptors not glycosylated at N(579), we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position. Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR). However, ligand drives the majority of N579Q-EGFR dimerization, suggesting that untethering, while necessary, is not sufficient to drive dimerization. Ligand-binding experiments reveal a much greater fraction of N579Q-EGFRs in a high-affinity state compared to the fraction of WT-EGFRs in a high-affinity state. However, differences in the kinetic association and dissociation rates indicate that the high-affinity states of the WT and the N579Q receptors are distinct. EGF-stimulated phosphorylation in cells expressing N579Q-EGFRs results in notable differences in the pattern of tyrosine phosphorylated proteins compared with that obtained in cells expressing WT-EGFRs. Moreover, although WT-EGFRs confer cell survival in 32D cells in the absence of interleukin-3 and EGF, we found that receptors lacking glycosylation at N(579) do not. This is the first study of which we are aware to show that selective glycosylation of a specific N-glycosylation site can produce two functionally distinct receptors.

N-Glycosylation at Asn Residues 554 and 566 of E-Cadherin Affects Cell Cycle Progression Through Extracellular Signal-Regulated Protein Kinase Signaling Pathway

N‐Glycosylation Affects the Adhesive Function of E‐Cadherin Through Modifying the Composition of Adherens Junctions (ajs) in Human Breast Carcinoma Cell Line MDA‐MB‐435

Unglycosylation at Asn-633 Made Extracellular Domain of E-cadherin Folded Incorrectly and Arrested in Endoplasmic Reticulum, then Sequentially Degraded by ERAD

N-Glycosylation at Asn 402 Stabilizes N-Cadherin and Promotes Cell-Cell Adhesion of Glioma Cells

Mutation of N-linked glycosylation in EpCAM affected cell adhesion in breast cancer cells

Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth

Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor

Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

N-linked Glycosylation at Asn152 on CD147 Affects Protein Folding and Stability: Promoting Tumour Metastasis in Hepatocellular Carcinoma

Deglycosylation Of Epithelial Cell Adhesion Molecule Affects Epithelial To Mesenchymal Transition In Breast Cancer Cells

Genetic and Epigenetic Regulation of E-Cadherin Signaling in Human Hepatocellular Carcinoma.

Nuclear E-cadherin acetylation promotes colorectal tumorigenesis via enhancing β-catenin activity.

The Role of Epithelial Cell Adhesion Molecule N-glycosylation on Apoptosis in Breast Cancer Cells

E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer

MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation.

p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry

Glycosylation Alters Dimerization Properties of a Cell-surface Signaling Protein, Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CEACAM1)

Driving Functional E-Cadherin Onto Cell Surface by Elevation of PKB Activity in SMMC 7721 Hepato-carcinoma Cells

TGF-β signaling links E-cadherin loss to suppression of nucleotide excision repair

Glycosylation at Asn254 Is Required for the Activation of the PDGF-C Protein

Bisecting N-Acetylglucosamine on EGFR Inhibits Malignant Phenotype of Breast Cancer Via Down-Regulation of EGFR/Erk Signaling